Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corporation demonstrated a strong financial position with a strengthened balance sheet, highlighted by securing up to $60 million in committed capital through a new five-year interest-only credit facility, extending debt maturity to 2031. The company's Q3 2025 revenue reached $21.5 million, reflecting a 5% year-over-year increase, with a solid gross margin of 75% and an improvement in gross profit to $17.5 million with a gross margin of 78%. Additionally, management's focus on cost restructuring, improved margins, and strategies to expand the eligible patient pool for treatment supports a positive outlook for sustainable growth and profitability.

Bears say

Pulmonx's financial performance in 2025 reveals modest annual growth of 8% with total revenue reaching $90.5 million; however, the fourth quarter exhibited a decline in revenue to $22.6 million, primarily due to weaker U.S. sales. The company experienced a significant decrease in cash, cash equivalents, and marketable securities, totaling $69.8 million at year-end, which marked a $32 million decline year over year, and it anticipates further cash depletion of approximately $23 million during 2026 without additional financing. Lastly, with operating expenses at $120.8 million and a net loss of $54 million, these factors contribute to a negative outlook for Pulmonx’s financial stability and operational effectiveness.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.